Immunic secures European patent extending MS drug exclusivity to 2038
European Patent Office granted IP patent EP3713554 for vidofludimus calcium, covering label-relevant dosing regimens and extending market protection in Europe to 2038, potentially to 2043 with a Supplementary Protection Certificate. Vidofludimus calcium is in Phase 3 trials for relapsing multiple sclerosis with top-line data expected by end-2026.
1. European Patent Grant
On March 10, the European Patent Office granted Immunic patent EP3713554 covering dosing regimens for vidofludimus calcium, securing market exclusivity in Europe until 2038.
2. Patent Scope and Potential Extension
The patent broadly protects the compound’s salt, solvate and free acid forms under the approved label and could extend exclusivity to 2043 if a Supplementary Protection Certificate is awarded.
3. Clinical Development Status
Vidofludimus calcium is an oral small-molecule therapy in Phase 3 trials for relapsing multiple sclerosis, with top-line efficacy and safety data anticipated by the end of 2026.
4. Global IP Landscape
Existing US patents protect composition of matter and treatment methods until 2041, while pending applications in Europe and other regions could push protection into the mid-2040s.